Table 2B
	% Blasts pre-LD	Allo-SCT Pre-CART	First absolute B-cell count (%)	Months after infusion Absolute loss BCA	Months after infusion Loss BCA Pennsyl	Months after infusion >1% B-cell at BM	Clinical decision after loss BCA	Relapse (Months after infusion)	Duration of remission since loss of BCA (months)	Intervention after relapse	Allo-SCT post CAR-T (Indication)	Last follow up (months after infusion)
1	0	Yes	9 (0,15)	9	11	9	Wait and see	No	Ongoing		No	Alive (34)
2	0	Yes	168 (20)	8	8	9	Wait and see	Yes (11)	3	Inotuzumab + reinfusion	No	Death (progression)
3	0	Yes	15 (0,5)	6	7	6	Wait and see Asp-PEG	Yes (16)	10	Inotuzumab	No	Alive. Palliative care (16)
4	0,01	No	20 (2)	6	6	Not reached	Wait and see	Yes (7)	1 (MRD relapse)	CART dual + Allo-SCT	Yes (relapse)	Alive (36)
5	0,46	Yes	22 (0,3)	8	8	6	Wait and see	No	Ongoing		No	Alive (27)
6	0	Yes	476 (14)	14	14	9	Wait and see	Yes (23)	9	Reinfusion	No	Alive. Palliative care (46)
7	0,03	Yes	111 (3)	18	18	12	Wait and see	No	Ongoing		No	Alive (42)
8	0,27	No	28 (7)	7	7	6	1° Allo-SCT	Yes (26)	19	Inotuzumab + 2° Allo-SCT	Yes (loss BCA)	Alive. Recent 2° Allo- SCT (26)
9	0,5	No	72 (4)	24	24	24	Wait and see	Yes (28)	4	Chemotherapy Waiting for 1° Allo-SCT	Yes (relapse)	Alive with disease (29)